
BioNTech SE BNTX
$ 89.55
-2.65%
Quarterly report 2025-Q4
added 05-07-2026
BioNTech SE EV - Enterprise Value 2011-2026 | BNTX
Annual EV - Enterprise Value BioNTech SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1 B | 16.3 B | 13.3 B | 16.4 B | 65.1 B | 17 B | 6.95 B | -25.5 M | 251 M | 358 M | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.1 B | -25.5 M | 15.3 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
4.15 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.3 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 16.87 | -2.49 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
43.4 M | $ 7.47 | -4.6 % | $ 205 M | ||
|
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
686 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
-5.73 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
AbCellera Biologics
ABCL
|
1.22 B | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Coherus BioSciences
CHRS
|
335 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.63 | 2.52 % | $ 434 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
11.4 M | - | - | $ 231 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 3.36 | -3.72 % | $ 5.53 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Eton Pharmaceuticals
ETON
|
599 M | $ 30.26 | 1.0 % | $ 814 M | ||
|
Exelixis
EXEL
|
11.9 B | $ 50.13 | -1.9 % | $ 13.6 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
122 M | $ 0.72 | -1.58 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
1.16 B | $ 3.12 | - | $ 649 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Fortress Biotech
FBIO
|
122 M | $ 2.41 | 4.78 % | $ 67.2 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Forte Biosciences
FBRX
|
280 M | $ 23.11 | -3.55 % | $ 299 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 21.32 | -1.16 % | $ 2.71 B | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
167 M | $ 9.75 | 5.52 % | $ 279 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M |